Navigation
Who we are
ASC Oncology was founded in 2019 by nine leading scientists in the fields of pathology, tumor biology, biochemistry, biotechnology and molecular biology to address one of the most important challenges in modern oncology: Providing patients with the right therapy at the right time. ASC Oncology offers patients and their treating physicians Reverse Clinical Engineering®, a cutting-edge technology designed to bridge the gap between current cancer research and clinical practice.
Our Vision
Our goal is to establish precision medicine as the standard in modern cancer therapy. Personalized therapy plans must become the rule. Among others, patients should receive treatment that is optimally tailored to them by use of the Reverse Clinical Engineering® test procedure. It is our common goal, and that of society and medicine, that no patient should die prematurely and avoidably from cancer. We are committed to this ‚Vision Zero‘ with our work. The focus is always on the patient, who is informed and involved in the treatment decision on an equal footing.
Our values
Our history and outlook
After developing the test procedure, Dr. Regenbrecht initially founded CELLphenomics GmbH together with Graf Adelmann in 2014. The company makes PD3D® cell culture-based services available for drug development and research.
In order to be able to offer the test procedure directly to physicians and patients as part of personalized medicine, ASC Oncology was founded in 2019. This was followed in 2021 by ASC Oncology Schweiz AG, the first sister company in Switzerland. A second laboratory is currently under construction in London, United Kingdom, and further outposts are planned in Dubai, United Arab Emirates, and Manipal, India.
Management
Christian RA Regenbrecht
Managing Director
Biologist, PhD
Co-founder of ASC Oncology GmbH
Quirin Graf Adelmann v. A.
Managing Director
Lawyer
Co-founder of ASC Oncology GmbH
Manuela Regenbrecht
Chief Medical Officer
Oncologist
Aline Freifrau von Godin
Business Development
Business Administrator, BSc
About Christian Regenbrecht
Dr. Christian Regenbrecht, developer of Reverse Clinical Engineering®, works with organoids in the field of systems medicine tumor research. He studied biology and philosophy at the Rheinische Friedrich-Wilhelms-Universität in Bonn and received his doctorate in 2005 under Otmar Wiestler at the University Hospital in Bonn. He then became a research associate with Hans Lehrach at the Max Planck Institute for Molecular Genetics in Berlin. He moved with his research group to the Charité in Berlin in 2010, where he headed the „Tumor Stem Cells“ research group at the Institute of Pathology until 2016, as well as the Charité’s central laboratory for functional genome research from 2012 to 2014. In addition to his work as CEO of CELLphenomics and ASC Oncology, he is a habilitand at the University Medical Center Göttingen since 2021.
„The diagnosis of cancer never affects only the patient himself; the disease also shocks and affects family and friends. In my family, my grandmother died of cancer. Therefore, my commitment to cancer patients is also shaped by my experience as a relative.“
Dr. Christian Regenbrecht
Managing Director ASC Oncology GmbH
Your contact persons
Sabine Finkler
Clinical Liaison Managerin
Chemist, Dr. rer. nat.
Larissa Ruhe
Clinical Liaison Managerin
Molecular biologist, Dr. rer. nat.
Advisory Board
Angela Brand
Prof. Dr. med.
Full Professor at the Faculty of Health, Medicine and Life Sciences (FHML)
Adjunct Professor at the School of Life Sciences, Manipal University, India
Professorial Fellow at the Maastricht Economic and Social Research Institute on Innovation and Technology
Director of the European Centre for Public Health Genomics (ECPHG)
Maastricht Wirtschafts- und Sozialforschungs-institut für Innovation und Technologie,
Professorin an der School of Life Science Manipal Universität
Saskia Biskup
Dr. med. Dr. rer. nat.
Co-founder of CeGaT GmbH
Own practice for human genetics in Tübingen
Bettina Ryll
Dr. med. Dr. rer.nat.
Chair of the ESMO Patient Advocates Working Group
Founder of the Melanoma Patient Network Europe
Cancer Mission board member at European Commission
Till Willebrand
Senior Company Manager Healthcare Industry at Berliner Sparkasse
Other associates
Michael Bitzer
Shareholder of ASC Oncology GmbH
Dr. med.
Senior Advisor
Christoph Reinhard
Co-founder of ASC Oncology GmbH
Dr. rer. nat.
Pharma Expert Translational Cancer Researcrte
Christoph Sachse
Co-founder of ASC Oncology GmbH
Dr. rer. nat.
VP Business Development
Nuvisan Innovation Campus Berlin
Philipp Ströbel
Co-founder of ASC Oncology GmbH
Pathologist, Prof. Dr. med.
Director of the Pathology Institute, Georg-August University Göttingen
Markus Templin
Co-founder of ASC Oncology GmbH
Biologist, Dr. rer. nat.
Inventor of the DigiWest Technology
